The United Kingdom and the United States have hammered out a key bilateral deal that will keep no tariffs on British pharmaceutical shipments entering the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to boost spending on medicines through the public health system. This commitment guarantees that duties on these key products will stay at zero for a duration of three years.
This development comes after previous warnings to dramatically increase duties on branded drug imports, with figures discussed up to 100%.
"This agreement between the Britain strengthens the international landscape for new treatments and establishes long-overdue balance to American-British medicine commerce," an announcement declared.
Trade Significance
Medicines are one of the Britain's most significant goods shipped to the US, which is clearly the largest destination for major UK drugmakers.
Statistics reveal that in the year to the end of September, the UK exported medicines valued at £11.1bn to the US. This value represented 17.4% of British export trade in that span.
"This guarantee safeguards jobs, increases funding and sets the stage for the UK to become a worldwide center for medical research," the Business and Trade Secretary stated.
Key NHS Changes
The agreement involves several notable commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it deems new medicines to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a aim to double total NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage manufacturers must return to the NHS to stay within budget will be limited at fifteen percent. Previously, rebates were more than twenty percent.
Broader Context
This agreement takes place against a long-running row between the drug companies and the British authorities over medicine costs and regulatory access.
This friction were intensified by arguments that US patients were charged several times more for the equivalent treatments than patients in the other developed nations.
Recently, several large manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been announced toward US facilities.
The Science Minister acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had declined as a share of its overall budget over the previous ten-year period.
